XOMA Ltd. (XOMA) said that it is expanding its development strategy for its XOMA 052 antibody to interleukin-1 beta to include effects on cholesterol lowering, reducing plaque deposits and damage to heart muscle and resulting long-term effects that can lead to heart attack, stroke and congestive heart failure.
XOMA's current XOMA 052 program is focused on Type 2 diabetes and this expansion represents an enormous increase in the number of patients who could be helped by this general anti-inflammatory approach.
The company is actively pursuing a partnership for the development and commercialization of XOMA 052.
For comments and feedback: editorial@rttnews.com